Rapid Micro Biosystems, Inc.

Rapid Micro Biosystems, Inc. is an innovative life sciences technology company dedicated to providing automated solutions for the rapid detection of microbial contamination in the manufacturing of healthcare products. The company's mission is to accelerate the detection of microbial contamination in pharmaceuticals, biologics, medical devices, and personal care products, thereby enabling the faster release of safe products and improving patient outcomes. Headquartered in Lexington, Massachusetts, with U.S. manufacturing operations in Lowell, Massachusetts, Rapid Micro Biosystems also maintains global locations in Switzerland, Germany, and the Netherlands.

At the core of its offerings is the Growth Direct® System, an automated, non-destructive, rapid microbial enumeration device. This platform automates traditional quality control (QC) microbiology testing workflows, replacing slow, manual processes to deliver faster contamination detection, reduced errors, and enhanced data integrity. The company's solutions cater to critical applications such as environmental monitoring, water testing, bioburden testing, and sterility testing across the pharmaceutical, biologics, medical device, and personal care product sectors. Beyond the Growth Direct® System, Rapid Micro Biosystems provides proprietary consumables, LIMS connection software like RMBNucleus Mold Alarm, and comprehensive customer support and validation services.

Led by President and CEO Robert Spignesi, Rapid Micro Biosystems positions itself as a key automation partner for the global biopharmaceutical industry. The company reported record preliminary unaudited fourth-quarter 2025 revenue of approximately $11.3 million, marking a 37% increase, and full-year 2025 revenue of approximately $33.6 million, a 20% increase over the prior year. Recent notable developments include a record multi-system order in Q4 2025 from a top 20 global biopharma customer and a follow-on multi-system order from Samsung Biologics in March 2026. While the company holds more cash than debt, it is currently unprofitable with weak gross profit margins.